Body composition derangements in lung cancer patients treated with first‐line pembrolizumab: A multicentre observational study

Abstract

Skeletal muscle abnormalities, apparently frequent in NSCLC, potentially represent intriguing predictive markers of response to ICIs and survival outcomes. Large prospective trials are needed to validate ICIs responders' clinical biomarkers.